Department of Surgery, Hahnemann University Hospital and Drexel University College of Medicine, Philadelphia, PA.
Department of Surgery, Hahnemann University Hospital and Drexel University College of Medicine, Philadelphia, PA.
Surgery. 2019 Aug;166(2):223-229. doi: 10.1016/j.surg.2019.04.020. Epub 2019 Jun 7.
Pancreaticoduodenectomy (PD) with right hemicolectomy (RH) to treat locally advanced right colon cancer (LARCC) has been rarely reported in the literature. Herein, we characterize clinicopathologic factors and evaluate outcomes of en bloc PD and RH for LARCC.
A systematic review of the literature was conducted on PubMed using MeSH terms ("pancreaticoduodenectomy" or "pancreas/surgery" or "duodenum/surgery" or "colectomy") and ("colonic neoplasms"). Data was extracted from patients who underwent en bloc PD and RH for LARCC. Factors investigated included patient demographics, surgical and pathologic parameters, postoperative complications, disease recurrence, and survival.
Our search yielded 27 articles (106 patients), including 1 case from our institution. Most patients were male (62.1%), median age 58 years (range 34-83). Surgical procedures performed included en bloc RH with PD (n = 91, 85.8%) and en bloc RH with pylorus-preserving PD (n = 15, 14.2%). Among reported, 95.5% of patients (n = 63), underwent R0 resection. One or more complications were reported in 33 patients (52.4%). Median survival was 168 months. Survival after resection was 75.9% at 2 years and 66.3% at 5 years. Overall survival was greater in patients with no lymph node involvement (IIC versus IIIC, hazard ratio 8.4, P = .003). Five-year survival for patients was 84.9% in patients with stage IIC versus 46.4% in patients with stage IIIC. There were 3 postoperative mortalities.
This data demonstrates that en bloc PD and RH is rarely performed yet can be a potentially safe treatment option in patients with LARCC. Lymph node involvement was the only independent prognostic factor.
胰十二指肠切除术(PD)联合右半结肠切除术(RH)治疗局部晚期右半结肠癌(LARCC)在文献中鲜有报道。在此,我们分析了 LARCC 行根治性 PD 和 RH 的临床病理特征并评估了其治疗效果。
我们在 PubMed 上使用 MeSH 术语(“胰十二指肠切除术”或“胰腺/手术”或“十二指肠/手术”或“结肠切除术”)和(“结肠肿瘤”)进行了文献系统性回顾。从接受 LARCC 根治性 PD 和 RH 的患者中提取数据。研究的因素包括患者人口统计学、手术和病理参数、术后并发症、疾病复发和生存情况。
我们的搜索结果显示 27 篇文章(106 例患者),包括我们机构的 1 例。大多数患者为男性(62.1%),中位年龄为 58 岁(范围 34-83 岁)。手术方式包括根治性 RH 联合 PD(n=91,85.8%)和保留幽门的 RH 联合 PD(n=15,14.2%)。报告中,95.5%(n=63)的患者行 R0 切除术。33 例(52.4%)患者报告有 1 种或多种并发症。中位生存时间为 168 个月。2 年和 5 年的切除后生存率分别为 75.9%和 66.3%。无淋巴结受累的患者(IIC 期与 IIIC 期相比,风险比 8.4,P=0.003)生存时间更长。IIC 期患者 5 年生存率为 84.9%,而 IIIC 期患者为 46.4%。术后有 3 例死亡。
该数据表明,根治性 PD 和 RH 虽然很少进行,但对于 LARCC 患者可能是一种安全的治疗选择。淋巴结受累是唯一独立的预后因素。